Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

12/18/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SEPN alert in real time by email

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

A live webcast will be available in the Investors & Media section of the company's website at www.septerna.com and will be archived for 30 days following the presentation.

About Septerna

Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.

Investor Contact:

Renee Leck

THRUST Strategic Communications

[email protected]

Media Contact:

Carly Scaduto

Carly Scaduto Consulting

[email protected]

Get the next $SEPN alert in real time by email

Date	Price Target	Rating	Analyst
11/19/2024	$38.00	Overweight	Analyst
11/19/2024		Buy	TD Cowen
11/19/2024	$43.00	Overweight	Wells Fargo
11/19/2024	$50.00	Overweight	Cantor Fitzgerald

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$SEPN

$SEPN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. converted options into 2,825,858 shares and bought $75,060,000 worth of shares (4,170,000 units at $18.00) (SEC Form 4)

Large owner Third Rock Ventures V, L.P. converted options into 7,663,729 shares and bought $11,700,000 worth of shares (650,000 units at $18.00) (SEC Form 4)

$SEPN
SEC Filings

SEC Form 10-Q filed by Septerna Inc.

Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 8-K filed by Septerna Inc.

$SEPN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. converted options into 2,825,858 shares and bought $75,060,000 worth of shares (4,170,000 units at $18.00) (SEC Form 4)

Large owner Third Rock Ventures V, L.P. converted options into 7,663,729 shares and bought $11,700,000 worth of shares (650,000 units at $18.00) (SEC Form 4)

$SEPN
Press Releases

Fastest customizable press release news feed in the world